Acute Kidney Injury

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Acute Kidney Injury

Description: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

  • Drug: Placebo
  • Drug: 800 mcg/kg ABT-719
  • Drug: 1200 mcg/kg ABT-719
  • Drug: 1200 mcg/kg ABT-719

 

Primary Investigator: Answini

Drug/Device Information
Subjects having a high risk for developing AKI who are undergoing pre-defined on-pump (cardiopulmonary bypass) cardiac surgery
ABT-719, a small peptide is a first-in-class, melanocortin (alpha-MSH) peptide analogue vs placebo
Randomized 1:1:1:1 (Placebo, 800 mcg/kg ABT-719, 1200 mcg/kg ABT-719, 1200 mcg/kg ABT-719
AbbVie